TY - JOUR
T1 - Model of complex chiral drug metabolic systems and numerical simulation of the remaining chirality toward analysis of dynamical pharmacological activity
AU - Ogino, Yoshiyuki
AU - Asahi, Toru
N1 - Funding Information:
The authors greatly appreciate Masahito Tanaka and Takuya Taniguchi for fruitful discussion. This study was financially supported by Grant-in-Aid for JSPS fellows (to Y.O.) from the Japanese Society for the Promotion of Science and the Global COE “Practical Chemical Wisdom” program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - In this study, systems of complicated pathways involved in chiral drug metabolism were investigated. The development of chiral drugs resulted in significant improvement in the remedies available for the treatment of various severe sicknesses. Enantiopure drugs undergo various biological transformations that involve chiral inversion and thus result in the generation of multiple enantiomeric metabolites. Identification of the specific active substances determining a given drug[U+05F3]s efficacy among such a mixture of different metabolites remains a challenge. To comprehend this complexity, we constructed a mathematical model representing the complicated metabolic pathways simultaneously involving chiral inversion. Moreover, this model is applied to the metabolism of thalidomide, which has recently been revived as a potentially effective prescription drug for a number of intractable diseases. The numerical simulation results indicate that retained chirality in the metabolites reflects the original chirality of the unmetabolized drug, and a higher level of enantiomeric purity is preserved during spontaneous degradation. In addition, chirality remaining after equilibration is directly related to the rate constant not only for chiral inversion but also for generation and degradation. Furthermore, the retention of chirality is quantitatively predictable using this combination of kinetic parameters. Our simulation results well explain the behavior of thalidomide in the practical biological experimental data. Therefore, this model promises a comprehensive understanding of dynamic metabolic systems involving chiral drugs that express multiple enantiospecific drug efficacies.
AB - In this study, systems of complicated pathways involved in chiral drug metabolism were investigated. The development of chiral drugs resulted in significant improvement in the remedies available for the treatment of various severe sicknesses. Enantiopure drugs undergo various biological transformations that involve chiral inversion and thus result in the generation of multiple enantiomeric metabolites. Identification of the specific active substances determining a given drug[U+05F3]s efficacy among such a mixture of different metabolites remains a challenge. To comprehend this complexity, we constructed a mathematical model representing the complicated metabolic pathways simultaneously involving chiral inversion. Moreover, this model is applied to the metabolism of thalidomide, which has recently been revived as a potentially effective prescription drug for a number of intractable diseases. The numerical simulation results indicate that retained chirality in the metabolites reflects the original chirality of the unmetabolized drug, and a higher level of enantiomeric purity is preserved during spontaneous degradation. In addition, chirality remaining after equilibration is directly related to the rate constant not only for chiral inversion but also for generation and degradation. Furthermore, the retention of chirality is quantitatively predictable using this combination of kinetic parameters. Our simulation results well explain the behavior of thalidomide in the practical biological experimental data. Therefore, this model promises a comprehensive understanding of dynamic metabolic systems involving chiral drugs that express multiple enantiospecific drug efficacies.
KW - Chemical reaction network
KW - Metabolic pathway of drug
KW - Molecular chirality
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=84926207749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926207749&partnerID=8YFLogxK
U2 - 10.1016/j.jtbi.2015.03.011
DO - 10.1016/j.jtbi.2015.03.011
M3 - Article
C2 - 25791284
AN - SCOPUS:84926207749
SN - 0022-5193
VL - 373
SP - 117
EP - 131
JO - Journal of Theoretical Biology
JF - Journal of Theoretical Biology
ER -